EMAIL THIS PAGE TO A FRIEND

American journal of physiology. Cell physiology

Atrial natriuretic peptide inhibits cell cycle activity of embryonic cardiac progenitor cells via its NPRA receptor signaling axis.


PMID 25631869

Abstract

The biological effects of atrial natriuretic peptide (ANP) are mediated by natriuretic peptide receptors (NPRs), which can either activate guanylyl cyclase (NPRA and NPRB) or inhibit adenylyl cyclase (NPRC) to modulate intracellular cGMP or cAMP, respectively. During cardiac development, ANP serves as an early maker of differentiating atrial and ventricular chamber myocardium. As development proceeds, expression of ANP persists in the atria but declines in the ventricles. Currently, it is not known whether ANP is secreted or the ANP-NPR signaling system plays any active role in the developing ventricles. Thus the primary aims of this study were to 1) examine biological activity of ANP signaling systems in embryonic ventricular myocardium, and 2) determine whether ANP signaling modulates proliferation/differentiation of undifferentiated cardiac progenitor cells (CPCs) and/or cardiomyocytes. Here, we provide evidence that ANP synthesized in embryonic day (E)11.5 ventricular myocytes is actively secreted and processed to its biologically active form. Notably, NPRA and NPRC were detected in E11.5 ventricles and exogenous ANP stimulated production of cGMP in ventricular cell cultures. Furthermore, we showed that exogenous ANP significantly decreased cell number and DNA synthesis of CPCs but not cardiomyocytes and this effect could be reversed by pretreatment with the NPRA receptor-specific inhibitor A71915. ANP treatment also led to a robust increase in nuclear p27 levels in CPCs compared with cardiomyocytes. Collectively, these data provide evidence that in the developing mammalian ventricles ANP plays a local paracrine role in regulating the balance between CPC proliferation and differentiation via NPRA/cGMP-mediated signaling pathways.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P3130
Propyl gallate, powder
C10H12O5
02370
Propyl gallate, for microscopy, ≥98.0% (HPLC)
C10H12O5
48710
Propyl gallate, antioxidant, ≥98.0% (HPLC)
C10H12O5
W294705
Propyl gallate, ≥98%, FCC
C10H12O5
1576800
Propyl gallate, United States Pharmacopeia (USP) Reference Standard
C10H12O5
P3640000
Propyl gallate, European Pharmacopoeia (EP) Reference Standard
C10H12O5
PHR1118
Propyl gallate, Pharmaceutical Secondary Standard; Certified Reference Material
C10H12O5
W302600
Sodium citrate dihydrate, ≥99%, FG
C6H5Na3O7 · 2H2O
S4641
Sodium citrate tribasic dihydrate, ACS reagent, ≥99.0%
C6H5Na3O7 · 2H2O
C7254
Sodium citrate tribasic dihydrate, ≥98%
C6H5Na3O7 · 2H2O
C8532
Sodium citrate tribasic dihydrate, for molecular biology, ≥99%
C6H5Na3O7 · 2H2O
C3434
Sodium citrate tribasic dihydrate, BioXtra, ≥99.0% (titration)
C6H5Na3O7 · 2H2O
71402
Sodium citrate tribasic dihydrate, BioUltra, for molecular biology, ≥99.5% (NT)
C6H5Na3O7 · 2H2O
C0909
Sodium citrate tribasic dihydrate, suitable for amino acid analysis, ≥98% (titration), powder
C6H5Na3O7 · 2H2O
C5920
Sodium citrate tribasic dihydrate, insect cell culture tested
C6H5Na3O7 · 2H2O
71404
Sodium citrate tribasic dihydrate, BioUltra, ≥99.0% (NT)
C6H5Na3O7 · 2H2O
71405
Sodium citrate tribasic dihydrate, puriss. p.a., ACS reagent, ≥99.0% (NT)
C6H5Na3O7 · 2H2O
71406
Sodium citrate tribasic dihydrate, purum p.a., ≥99.0% (NT)
C6H5Na3O7 · 2H2O
71409
Sodium citrate tribasic dihydrate, tested according to Ph.Eur.
C6H5Na3O7 · 2H2O
S1804
Trisodium citrate dihydrate, meets USP testing specifications
C6H5Na3O7 · 2H2O